Metastatic Prostate Cancer
VIDEO: Combo therapy improves outcomes for Black patients with metastatic prostate cancer
CHICAGO — In this Healio video exclusive, Andrew Armstrong, MD, discusses the results of the use of abiraterone acetate and apalutamide plus prednisone in Black and White patients with metastatic castrate-resistant prostate cancer.
Half of men with metastatic prostate cancer face treatment-related financial toxicity
More than half of men treated for metastatic prostate cancer reported experiencing some degree of financial hardship, according to study results published in The Journal of Urology.
Cabozantinib-atezolizumab combination extends PFS in metastatic prostate cancer
The combination of cabozantinib and atezolizumab prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer, according to a topline data announcement.
VIDEO: Treatment intensification in metastatic prostate cancer ‘underutilized’
CHICAGO — In this video, Stephen J. Freedland, MD, discusses how intensification of androgen deprivation therapy using novel hormonal therapies remains underutilized in patients with de novo metastatic castration-sensitive prostate cancer.
FDA approves Talzenna regimen for certain men with metastatic prostate cancer
FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset
CHICAGO Adding prostate irradiation to standard systemic therapy extended radiographic PFS among men with newly diagnosed low-volume metastatic castration-sensitive prostate cancer, according to results of the PEACE-1 trial.
Talazoparib regimen improves outcomes among subset of men with metastatic prostate cancer
CHICAGO — Adding talazoparib to enzalutamide reduced the risk for disease progression or death by 55% in certain men with metastatic castration-resistant prostate cancer, results of the randomized phase 3 TALAPRO-2 trial showed.
Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume
Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.
Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations
SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.
Talazoparib regimen improves outcomes among certain men with metastatic prostate cancer
SAN FRANCISCO — The addition of talazoparib to first-line enzalutamide extended imaging-based PFS among men with metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 TALAPRO-2 study.